-
公开(公告)号：US08586588B2
公开(公告)日：2013-11-19
申请号：US12815813
申请日：2010-06-15
申请人： Edward R. Bacon , Thomas R. Bailey , Nadine C. Becknell , Sankar Chatterjee , Derek Dunn , Greg A. Hostetler , Robert L. Hudkins , Kurt A. Josef , Lars J. S. Knutsen , Ming Tao , Allison L. Zulli
发明人： Edward R. Bacon , Thomas R. Bailey , Nadine C. Becknell , Sankar Chatterjee , Derek Dunn , Greg A. Hostetler , Robert L. Hudkins , Kurt A. Josef , Lars J. S. Knutsen , Ming Tao , Allison L. Zulli
IPC分类号： C07D403/12 , C07D401/14 , A61K31/501 , A61P25/20 , A61P3/04 , A61P25/18 , A61P29/00 , A61P25/06 , A61P25/24 , A61P25/08
CPC分类号： C07D498/04 , C07D237/14 , C07D237/26 , C07D237/32 , C07D237/36 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D409/04 , C07D495/04
摘要： The present invention is directed to novel pyridazinone derivatives that mediate enzymatic activity. In particular, the compounds and/or their pharmaceutically acceptable salts may be effective in the treatment of diseases or disease states related to the activity of the histamine H3 receptor, including, for example, neurodegenerative disorders, sleep/wake disorders, attention deficit hyperactivity disorder and cognition/cognitive disorders.
摘要翻译： 本发明涉及介导酶活性的新的哒嗪酮衍生物。 特别地，化合物和/或其药学上可接受的盐可有效治疗与组胺H3受体活性相关的疾病或疾病状态，包括例如神经变性障碍，睡眠/觉醒障碍，注意缺陷多动障碍 和认知/认知障碍。
-
公开(公告)号：US08207168B2
公开(公告)日：2012-06-26
申请号：US12815800
申请日：2010-06-15
申请人： Nadine C. Becknell , Derek Dunn , Robert L. Hudkins , Kurt A. Josef , Lars J. S. Knutsen , Ming Tao , Allison L. Zulli
发明人： Nadine C. Becknell , Derek Dunn , Robert L. Hudkins , Kurt A. Josef , Lars J. S. Knutsen , Ming Tao , Allison L. Zulli
IPC分类号： A61K31/501 , A61K31/502 , C07D401/14 , C07D237/32 , C07D237/26 , C07D403/04 , A61P3/04 , A61P25/28 , A61P25/18 , A61P25/04 , A61P25/06 , A61P25/08 , A61P25/24 , A61P11/06 , A61P29/00 , A61P9/10
CPC分类号： C07D498/04 , C07D237/14 , C07D237/26 , C07D237/32 , C07D237/36 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D409/04 , C07D495/04
摘要： The present invention is directed to novel pyridazinone derivatives that mediate enzymatic activity. In particular, the compounds may be effective in the treatment of diseases or disease states related to the activity of the histamine H3 receptor, including, for example, neurodegenerative disorders, sleep/wake disorders, attention deficit hyperactivity disorder and cognition disorders.
摘要翻译： 本发明涉及介导酶活性的新的哒嗪酮衍生物。 特别地，所述化合物可有效治疗与组胺H3受体活性相关的疾病或疾病状态，包括例如神经退行性疾病，睡眠/觉醒障碍，注意缺陷多动障碍和认知障碍。
-
3.发明授权Methods of treating disorders mediated by histamine H3 receptors using pyridazinone derivatives 有权使用哒嗪酮衍生物治疗由组胺H3受体介导的病症的方法公开(公告)号：US08673916B2
公开(公告)日：2014-03-18
申请号：US13197243
申请日：2011-08-03
申请人： Edward R. Bacon , Thomas R. Bailey , Nadine C. Becknell , Sankar Chatterjee , Derek D. Dunn , Greg A. Hostetler , Robert L. Hudkins , Kurt A. Josef , Lars J. S. Knutsen , Ming Tao , Allison L. Zulli
发明人： Edward R. Bacon , Thomas R. Bailey , Nadine C. Becknell , Sankar Chatterjee , Derek D. Dunn , Greg A. Hostetler , Robert L. Hudkins , Kurt A. Josef , Lars J. S. Knutsen , Ming Tao , Allison L. Zulli
CPC分类号： C07D498/04 , C07D237/14 , C07D237/26 , C07D237/32 , C07D237/36 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D409/04 , C07D495/04
摘要： The present invention is directed to methods of treating disorders mediated by Histamine H3 receptors by administering novel pyridazinone derivatives. In particular, the pyridazinone compounds may be effective in the treatment of diseases or disease states related to the activity of the histamine H3 receptor, including, for example, neurodegenerative disorders, sleep/wake disorders, attention deficit hyperactivity disorder and cognition/cognitive disorders.
摘要翻译： 本发明涉及通过施用新的哒嗪酮衍生物治疗由组胺H3受体介导的病症的方法。 特别地，哒嗪酮化合物可有效治疗与组胺H3受体活性相关的疾病或疾病状态，包括例如神经退行性疾病，睡眠/觉醒障碍，注意缺陷多动障碍和认知/认知障碍。
-
公开(公告)号：US20100280007A1
公开(公告)日：2010-11-04
申请号：US12815800
申请日：2010-06-15
申请人： Edward R. Bacon , Thomas R. Bailey , Nadine C. Becknell , Sankar Chatterjee , Derek Dunn , Greg A. Hostetler , Robert L. Hudkins , Kurt A. Josef , Lars J.S. Knutsen , Ming Tao , Allison L. Zulli
发明人： Edward R. Bacon , Thomas R. Bailey , Nadine C. Becknell , Sankar Chatterjee , Derek Dunn , Greg A. Hostetler , Robert L. Hudkins , Kurt A. Josef , Lars J.S. Knutsen , Ming Tao , Allison L. Zulli
IPC分类号： A61K31/55 , A61K31/5377 , A61K31/502 , A61K31/501 , C07D413/12 , C07D498/04 , C07D403/12 , A61P25/00 , A61P3/04 , A61P25/28 , A61P25/18 , A61P25/08 , A61P11/00 , A61P25/24 , A61P29/00 , A61P9/10 , A61P1/00 , A61P25/06 , A61P43/00 , C07D495/04 , C07D401/14 , C07D409/14 , A61K31/5025
CPC分类号： C07D498/04 , C07D237/14 , C07D237/26 , C07D237/32 , C07D237/36 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D409/04 , C07D495/04
摘要： The present invention is directed to novel pyridizinone derivatives that mediate enzymatic activity. In particular, the compounds may be effective in the treatment of diseases or disease states related to the activity of the histamine H3 receptor, including, for example, neurodegenerative disorders, sleep/wake disorders, attention deficit hyperactivity disorder and cognition.
-
公开(公告)号：US08247414B2
公开(公告)日：2012-08-21
申请号：US11881001
申请日：2007-07-25
申请人： Edward R. Bacon , Nadine C. Becknell , Sankar Chatterjee , Derek Dunn , Robert L. Hudkins , Kurt A. Josef , Ming Tao , Allison L. Zulli
发明人： Edward R. Bacon , Nadine C. Becknell , Sankar Chatterjee , Derek Dunn , Robert L. Hudkins , Kurt A. Josef , Ming Tao , Allison L. Zulli
IPC分类号： C07D401/14 , C07D237/26 , C07D498/04 , C07D237/36 , A61K31/501 , A61K31/502 , A61K31/5025 , C07D403/12 , C07D237/32 , C07D237/14 , C07D237/00 , C07D413/12 , A61K31/55 , A61K31/5355
CPC分类号： C07D498/04 , C07D237/14 , C07D237/26 , C07D237/32 , C07D237/36 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D409/04 , C07D495/04
摘要： The present invention is directed to novel pyridizinone derivatives that mediate enzymatic activity. In particular, the compounds may be effective in the treatment of diseases or disease states related to the activity of the histamine H3 receptor, including, for example, neurodegenerative disorders, sleep/wake disorders, attention deficit hyperactivity disorder and cognition.
摘要翻译： 本发明涉及介导酶活性的新型吡哒嗪酮衍生物。 特别地，这些化合物可有效治疗与组胺H3受体活性相关的疾病或疾病状态，包括例如神经变性疾病，睡眠/觉醒障碍，注意力缺陷多动障碍和认知。
-
公开(公告)号：US20110288075A1
公开(公告)日：2011-11-24
申请号：US13197243
申请日：2011-08-03
申请人： Edward R. Bacon , Thomas R. Bailey , Nadine C. Becknell , Sankar Chatterjee , Derek Dunn , Greg A. Hostetler , Robert L. Hudkins , Kurt A. Josef , Lars J.S. Knutsen , Ming Tao , Allison L. Zulli
发明人： Edward R. Bacon , Thomas R. Bailey , Nadine C. Becknell , Sankar Chatterjee , Derek Dunn , Greg A. Hostetler , Robert L. Hudkins , Kurt A. Josef , Lars J.S. Knutsen , Ming Tao , Allison L. Zulli
IPC分类号： A61K31/55 , A61K31/502 , A61K31/5025 , A61P25/00 , A61K31/50 , A61P25/28 , A61P25/18 , A61K31/501 , A61K31/5377
CPC分类号： C07D498/04 , C07D237/14 , C07D237/26 , C07D237/32 , C07D237/36 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D409/04 , C07D495/04
摘要： The present invention is directed to novel pyridazinone derivatives that mediate enzymatic activity. In particular, the compounds may be effective in the treatment of diseases or disease states related to the activity of the histamine H3 receptor, including, for example, neurodegenerative disorders, sleep/wake disorders, attention deficit hyperactivity disorder and cognition/cognitive disorders.
摘要翻译： 本发明涉及介导酶活性的新的哒嗪酮衍生物。 特别地，这些化合物可有效治疗与组胺H3受体活性相关的疾病或疾病状态，包括例如神经变性疾病，睡眠/觉醒障碍，注意缺陷多动障碍和认知/认知障碍。
-
公开(公告)号：US20100273779A1
公开(公告)日：2010-10-28
申请号：US12815813
申请日：2010-06-15
申请人： Edward R. Bacon , Thomas R. Bailey , Nadine C. Becknell , Sankar Chatterjee , Derek Dunn , Greg A. Hostetler , Robert L. Hudkins , Kurt A. Josef , Lars J.S. Knutsen , Ming Tao , Allison L. Zulli
发明人： Edward R. Bacon , Thomas R. Bailey , Nadine C. Becknell , Sankar Chatterjee , Derek Dunn , Greg A. Hostetler , Robert L. Hudkins , Kurt A. Josef , Lars J.S. Knutsen , Ming Tao , Allison L. Zulli
IPC分类号： A61K31/55 , C07D403/12 , A61K31/501 , A61K31/502 , C07D495/04 , A61P3/04 , A61P9/10 , A61P11/00 , A61P25/08 , A61P25/18 , A61P25/24 , A61P25/28 , A61P1/00 , A61P29/00
CPC分类号： C07D498/04 , C07D237/14 , C07D237/26 , C07D237/32 , C07D237/36 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D409/04 , C07D495/04
摘要： The present invention is directed to novel pyridizinone derivatives that mediate enzymatic activity. In particular, the compounds may be effective in the treatment of diseases or disease states related to the activity of the histamine H3 receptor, including, for example, neurodegenerative disorders, sleep/wake disorders, attention deficit hyperactivity disorder and cognition.
摘要翻译： 本发明涉及介导酶活性的新型吡哒嗪酮衍生物。 特别地，这些化合物可有效治疗与组胺H3受体活性相关的疾病或疾病状态，包括例如神经变性疾病，睡眠/觉醒障碍，注意力缺陷多动障碍和认知。
-
公开(公告)号：US20140142088A1
公开(公告)日：2014-05-22
申请号：US14083013
申请日：2013-11-18
申请人： Edward R. Bacon , Thomas R. Bailey , Nadine C. Becknell , Sankar Chatterjee , Derek Dunn , Greg A. Hostetler , Robert L. Hudkins , Kurt A. Josef , Lars J.S. Knutsen , Ming Tao , Alison L. Zulli
发明人： Edward R. Bacon , Thomas R. Bailey , Nadine C. Becknell , Sankar Chatterjee , Derek Dunn , Greg A. Hostetler , Robert L. Hudkins , Kurt A. Josef , Lars J.S. Knutsen , Ming Tao , Alison L. Zulli
IPC分类号： C07D498/04 , C07D237/14 , C07D409/04 , C07D237/26 , C07D401/12 , C07D401/14 , C07D403/12 , C07D495/04
CPC分类号： C07D498/04 , C07D237/14 , C07D237/26 , C07D237/32 , C07D237/36 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D409/04 , C07D495/04
摘要： The present invention is directed to novel pyridazinone derivatives that mediate enzymatic activity. In particular, the compounds may be effective in the treatment of diseases or disease states related to the activity of the histamine H3 receptor, including, for example, neurodegenerative disorders, sleep/wake disorders, attention deficit hyperactivity disorder and cognition.
摘要翻译： 本发明涉及介导酶活性的新的哒嗪酮衍生物。 特别地，这些化合物可有效治疗与组胺H3受体活性相关的疾病或疾病状态，包括例如神经变性疾病，睡眠/觉醒障碍，注意力缺陷多动障碍和认知。
-
9.发明申请Substituted Pyridazinone Derivatives as Histamine-3 (H3) Receptor Ligands 审中-公开作为组胺-3（H3）受体配体的取代哒嗪酮衍生物公开(公告)号：US20110098269A1
公开(公告)日：2011-04-28
申请号：US12948496
申请日：2010-11-17
申请人： Nadine C. Becknell , Reddeppa reddy Dandu , Derek D. Dunn , Robert L. Hudkins , Kurt A. Josef , Babu G. Sundar , Allison L. Zulli
发明人： Nadine C. Becknell , Reddeppa reddy Dandu , Derek D. Dunn , Robert L. Hudkins , Kurt A. Josef , Babu G. Sundar , Allison L. Zulli
IPC分类号： A61K31/501 , C07D403/10 , C07D401/14 , C07D403/14 , C07D237/14 , C07D401/10 , C07D413/10 , A61K31/55 , A61K31/4985 , A61K31/5377 , A61P3/00 , A61P3/04 , A61P25/00 , A61P25/20 , A61P25/28 , A61P25/18 , A61P25/22 , A61P25/06 , A61P25/04 , A61P25/24 , A61P25/08 , A61P29/00 , A61P9/10 , A61P1/00 , A61P11/00
CPC分类号： C07D403/04 , C07D237/14 , C07D401/14 , C07D403/10 , C07D403/12 , C07D487/04
摘要： The present invention provides compounds according to Formulas I, II, III, IV, V, VI, VII or VIII: their use as H3 antagonists/inverse agonists, processes for their preparation, and pharmaceutical compositions thereof.
摘要翻译： 本发明提供了根据式I，II，III，IV，V，VI，VII或VIII的化合物：它们用作H3拮抗剂/反向激动剂，其制备方法及其药物组合物。
-
公开(公告)号：US20100152196A1
公开(公告)日：2010-06-17
申请号：US12708306
申请日：2010-02-18
申请人： Nadine C. Becknell , James L. Diebold , Diane E. Gingrich , Robert L. Hudkins , Dandu R. Reddy , Ming Tao , Theodore L. Underiner , Allison L. Zulli
发明人： Nadine C. Becknell , James L. Diebold , Diane E. Gingrich , Robert L. Hudkins , Dandu R. Reddy , Ming Tao , Theodore L. Underiner , Allison L. Zulli
IPC分类号： A61K31/501 , A61K31/506 , A61K31/4439 , A61K31/4162 , C07D487/14 , A61P25/16 , A61P25/00 , A61P25/28
CPC分类号： C07D487/14 , C07D487/04
摘要： The present invention relates generally to selected fused pyrrolocarbazoles, including pharmaceutical compositions thereof and methods of treating diseases therewith. The present invention is also directed to intermediates and processes for making these fused pyrrolocarbazoles.
摘要翻译： 本发明一般涉及选择的稠合吡咯并唑，包括其药物组合物和用其治疗疾病的方法。 本发明还涉及制备这些稠合的吡咯并咔唑的中间体和方法。
-
-
-
-
-
-
-
-
-
搜索结果
21 条记录 (耗时 0.065 秒)
